Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation
Article first published online: 30 APR 2007
Volume 27, Issue 6, pages 758–763, August 2007
How to Cite
Botha, J. F., Thompson, E., Gilroy, R., Grant, W. J., Mukherjee, S., Lyden, E. R., Fox, I. J., Sudan, D. L., Shaw, B. W. and Langnas, A. N. (2007), Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver International, 27: 758–763. doi: 10.1111/j.1478-3231.2007.01490.x
- Issue published online: 30 APR 2007
- Article first published online: 30 APR 2007
- Received 30 January 2007accepted 26 February 2007
- donor steatosis;
- hepatitis C;
- virus – recurrence
Background: This study examines the impact of donor liver macrovesicular steatosis on recurrence of hepatitis C virus (HCV) disease after liver transplantation.
Methods: Between 1998 and 2004, 113 patients underwent liver transplantation for HCV-related cirrhosis. Time to histologic recurrence (fibrosis score ≥2) was the primary endpoint of the study. Recurrence was graded according to the system of Ludwig and Batts. A Cox's proportional hazard regression model was used to analyse the association between donor liver steatosis and HCV recurrence.
Results: Recurrence-free survival for patients who received steatotic grafts was 82% and 47% at 1 and 4 years, respectively, and 81% and 52% for patients who received a non-steatotic liver. Donor macrovesicular steatosis (5–45%) was found to have no impact on HCV recurrence (P=0.47). Donor age (P=0.02) and cold ischaemia time (P=0.01) were found to increase the relative risk of HCV recurrence. The estimated risk of HCV recurrence increased by 23% for every 10-year increase in donor age. Similarly the risk of recurrence increased by 13% for every 1-h increase in cold ischaemia time.
Conclusion: Mild-moderate donor liver macrovesicular steatosis has no impact on HCV recurrence after liver transplantation for HCV-related cirrhosis. Cold ischaemia time and donor age increased the likelihood of HCV recurrence.